AzTrials
AzTrials

Ventricular TachycardiaNCT03437408

Late Potentials and Ablation Index in Ventricular Tachycardia Ablation

A study testing Mapping and ablation in people with Ventricular Tachycardia, run by University Hospital Southampton NHS Foundation Trust at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

There is an increasing evidence regarding the efficacy of a substrate-based ablation approach to ventricular tachycardia (VT). This approach involves identifying regions of scar and also areas displaying late potentials and fractionated activity. Read more about this study

Who is it for?
Ages 18 to 100 years
Conditions the study is for
Ventricular Tachycardia
What is being tested?
Mapping and ablation
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
1 siteUnited Kingdom
Study dates
26 Jun 2019to 22 Oct 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Ventricular Tachycardia; scheduled for ablation on clinical grounds; able/willing to consent to procedure/research protocol; no contraindication to clinical ablation; ≥18 years old

Who cannot join

  • Unable/unwilling to consent; contraindication to clinical ablation

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Southampton General Hospital

    Southampton, Hampshire, SO16 6YD

Other trials in United Kingdom

About this study

Official title: Influence of Ventricular Pacing on Automated Ventricular Substrate Mapping and Relationship Between Ablation Index and Impedance Drop in the Human Ventricle

There is an increasing evidence regarding the efficacy of a substrate-based ablation approach to ventricular tachycardia (VT). This approach involves identifying regions of scar and also areas displaying late potentials and fractionated activity. Automated mapping systems are now available which may be able to generate high density maps displaying regions containing both late potentials and ventricular scar. Such an automated approach has not been validated. Furthermore, most patients presenting for VT ablation have pacing devices in situ. It is not known how the pacing modality affect the substrate maps generated for these procedures. Once an area felt to be important to ablate has been identified, the next key step is to perform effective ablation. An algorithm has now been made available (Ablation index - Biosense Webster Inc.,) which in preclinical studies is an effective predictor of radiofrequency lesion depth. This algorithm has been studied extensively in the atrium but not in the ventricle. This study would also seek to collect ablation index data during ablation to assess the algorithm during ventricular ablation.

Read the detailed description

The study would propose to use the Carto3 mapping system with the Confidense automated tagging module (Biosense Webster Inc.,) and a high density mapping catheter to generate substrate maps of the ventricle, with maps generated with varying pacing modes. A SmartTouch catheter (Biosense Webster Inc.,) would then be used for ablation with data collected during each ablation.

The study hypotheses are:

  • High density automated mapping systems can be used to generate accurate ventricular substrate maps.
  • There will be a significant change in the late potential maps based on the presence and type of ventricular pacing.
  • The relationship between impedance drop and ablation index during ablation will be stronger than FTI and will allow formulation of an upper limit for clinical ventricular ablation.
  • The relationship between FTI and AI with impedance drop will be stronger than with electrogram attenuation.

Protocol:

15 patients, listed on clinical grounds for a left ventricular VT ablation in the context of structural heart disease (including redo ablation) would be recruited for the trial. All patients would need to have a pacing device in situ and have underlying sensed ventricular rhythm (with or without atrial pacing), or in the absence of a sensed ventricular rhythm, a biventricular pacing device. As part of their clinical work-up for the procedure, patients will have cardiac MRI scans wherever possible.

All procedures would be undertaken with Carto3, using a PentaRay catheter for mapping in concert with the Confidense module, and a SmartTouch or SmartTouch SF catheter for ablation (Biosense Webster).

Procedures would be conducted under moderate ('conscious') sedation or general anaesthetic.

Mapping Phase Mapping would be performed antegrade, retrograde or a combination of both. The first map taken would be without ventricular pacing using the PentaRay catheter and Confidense. Confidense maps would be displayed showing bipolar voltage and late potentials in Carto3. The aim would be for maximal coverage of the ventricle. A remap would then be undertaken with pacing from the patient's right ventricular pacing lead. In patients with an additional left ventricular lead, maps would also be made with left ventricular only and biventricular pacing. In those patient without underlying ventricular sensed rhythm, maps would be taken with right ventricular only, left ventricular only and biventricular pacing.

The automatically collected maps would then be validated. The PentaRay would be moved over to 2 areas where there is agreement between the maps over the presence of late potentials and, while the PentaRay was kept in the same place, manual points would be taken with one pacing mode and then with the pacing mode changed. This would also be repeated for 2 areas where there is disagreement over the presence of late potentials. This process would also be repeated for areas identified as showing scar. All points would be taken with respiratory gating. Off line, the areas identified as showing abnormal signal - either scar or late potentials - would be manually checked to ensure the system has correctly identified them.

Ablation Phase Ablation would be undertaken using a Smart Touch Surround Flow Catheter (Biosense Webster). Ablation power would be restricted to 40-50W based on the operator's choice. Steerable sheath usage would be encouraged but not mandatory. Each radiofrequency application would be delivered with the catheter stable prior to the ablation. A mapping point would be taken with the catheter stable, and then a static ablation would be delivered and an ablation point manually taken. Following cessation of ablation, a further mapping point would be taken. All points would be respiratory gated. Ablations would be non-overlapping. If there was displacement of the catheter during the ablation, this ablation would be removed from the impedance analysis.

Quantitative comparisons Mapping Study The percentage of the maps showing scar and late potentials would be quantitatively analysed by exporting the data from Carto3. As comparisons would be made between pacing modes, each patient would act as their own control. Based on prior work, bipolar scar would be defined as <0.5mv for dense scar and 0.5-1.5mV for low voltage areas12, while unipolar scar would be <5mV. The characteristic of the late potentials - specifically how late they were compared to the QRS and their size would be compared quantitatively for electrograms taken manually at the same location with the PentaRay. Quantitative analyses of the data exported from Carto 3 would be conducted using novel algorithms programmed in Matlab (Mathworks, Natick, MA, USA).

Ablation Study The Carto3 data export would be utilized to obtain the impedance, contact force, temperature and location data and electrogram data (pre- and post-ablation) for each ablation. These data would then be analysed using custom Matlab scripts to undertake an incremental AI and FTI based analysis of the impedance drop during ablation. The curves would then be analyzed with the target of quantitatively describing the relationships with impedance drop and if possible providing the plateau points in the curve to generate an upper limit for ablation.

Value of Results This study would assess automated electrogram collection as a valid methodology for rapidly generating ventricular substrate maps. This will help to shorten procedure times for VT ablation by guiding the physician to the areas of interest more rapidly. At present, it is unknown how the pacing mode affects substrate maps in the ventricle and consequently the mode in which to leave pacing. The study will help to guide us to maximise the appropriate identification of the VT substrate by picking the correct pacing mode for the procedure.

The study would validate the use of ablation index for clinical ventricular ablation as well as aiming to provide guidance as to how to use this for maximal safety and efficacy.

Being tested
Mapping and ablation
Keywords
Ventricular Tachycardia, Catheter Ablation, Late Potential, Ablation Index, Pacing
Medical subject headings
Tachycardia, Ventricular

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mapping and ablationDevice

    High density substrate map. Data collection during ablation

Study groups in NCT03437408
Study groupRoleWhat they receive
Mapping and ablationExperimentalAutomated Substrate maps with different pacing modes. Validation of collected substrate. Data collection during ablation
Receives: Device: Mapping and ablation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Areas with ventricular tachycardia substrate

    Quantification of late potential area and scar area with comparison between pacing modalities

    Measured: Through study completion, an average of 1 year

Secondary outcomes (3)
  1. Relationship between ablation index and impedance drop

    Quantification of the relationship between ablation index and impedance drop during ablation.

    Measured: Through study completion, an average of 1 year

  2. Relationship between Force Time Integral and impedance drop

    Quantification of the relationship between Force Time Integral and impedance drop during ablation.

    Measured: Through study completion, an average of 1 year

  3. Relationship between electrogram attenuation and impedance drop

    Quantification of the relationship between electrogram attenuation and impedance drop during ablation.

    Measured: Through study completion, an average of 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Feb 2018
  2. Study start26 Jun 2019
  3. Primary completion22 Oct 2020
  4. Study completion22 Oct 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Model description
Ventricular Substrate maps in patients undergoing ablation for VT - maps collected with automated tagging in different pacing modalities. Validation of collected substrate. Collection of impedance and ablation index data during ablation
Masking
None (open label)
Enrolment
15 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03437408
Sponsor's protocol ID
RHM CAR0538
Status last verified
Sep 2021
First submitted
2 Feb 2018
Last updated
29 Sep 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: No plans to share IPD

Publications

  • Bates AP, Paisey J, Yue A, Banks P, Roberts PR, Ullah W. Radiofrequency Ablation of the Diseased Human Left Ventricle: Biophysical and Electrogram-Based Analysis. JACC Clin Electrophysiol. 2023 Mar;9(3):330-340. doi: 10.1016/j.jacep.2022.10.001. Epub 2022 Oct 10.

    PubMed 36371330

Questions about this trial

What is this clinical trial studying?

A study testing Mapping and ablation in people with Ventricular Tachycardia, run by University Hospital Southampton NHS Foundation Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Areas with ventricular tachycardia substrate (time frame: Through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03437408, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in